GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Repurchase of Stock

Avalo Therapeutics (Avalo Therapeutics) Repurchase of Stock : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Avalo Therapeutics Repurchase of Stock?

Avalo Therapeutics's Repurchase of Stock for the three months ended in Mar. 2024 was $0.00 Mil.

Avalo Therapeutics's Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Avalo Therapeutics Repurchase of Stock Historical Data

The historical data trend for Avalo Therapeutics's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Repurchase of Stock Chart

Avalo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -14.81 -

Avalo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Avalo Therapeutics Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalo Therapeutics (Avalo Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Repurchase of Stock
Comparable Companies
KALA FBRX TCRT EQ PMCB FRES IGC AKTX MYMD NTRB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
C6K0:Germany C6K0:Germany
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Website
https://www.avalotx.com
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.
Executives
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Caissa Capital Management Ltd. 10 percent owner PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110
Christopher Ryan Sullivan officer: Interim CFO C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Garry Arthur Neil officer: Chief Medical Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Mitchell Chan director C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Stephen Smolinski officer: Chief Commercial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Magnus Persson director 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Joseph M Miller director C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Gilla Kaplan director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Schond L. Greenway officer: CFO & Treasurer C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
H Jeffrey Wilkins officer: Chief Medical Officer 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Harrell James Archie Jr officer: Chief Commercial Officer C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022